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OBJECTIVE — Weight loss through lifestyle changes is recommended for nonalcoholic fatty
liver disease (NAFLD). However, its efﬁcacy in patients with type 2 diabetes is unproven.
RESEARCH DESIGN AND METHODS — Look AHEAD (Action for Health in Diabe-
tes) is a 16-center clinical trial with 5,145 overweight or obese adults with type 2 diabetes, who
were randomly assigned to an intensive lifestyle intervention (ILI) to induce a minimum weight
loss of 7% or a control group who received diabetes support and education (DSE). In the Fatty
Liver Ancillary Study, 96 participants completed proton magnetic resonance spectroscopy to
quantify hepatic steatosis and tests to exclude other causes of liver disease at baseline and 12
months. We deﬁned steatosis 5.5% as NAFLD.
RESULTS — Participantswere49%womenand68%white.Themeanagewas61years,mean
BMI was 35 kg/m
2, mean steatosis was 8.0%, and mean aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) were 20.5 and 24.2 units/l, respectively. After 12 months,
participants assigned to ILI (n  46) lost more weight (8.5 vs. 0.05%; P  0.01) than those
assignedtoDSEandhadagreaterdeclineinsteatosis(50.8vs.22.8%;P0.04)andinA1C
(0.7 vs. 0.2%; P  0.04). There were no signiﬁcant 12-month changes in AST or ALT levels.
At 12 months, 26% of DSE participants and 3% (1 of 31) of ILI participants without NAFLD at
baseline developed NAFLD (P  0.05).
CONCLUSIONS — A 12-month intensive lifestyle intervention in patients with type 2 dia-
betes reduces steatosis and incident NAFLD.
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N
onalcoholic fatty liver disease
(NAFLD) is one of the most com-
mon chronic liver diseases in the
generalpopulationwithupto20–30%of
adults having hepatic steatosis. Further-
more, NAFLD is known to lead to serious
liver-related complications and cardio-
vascular disease, especially in individuals
with type 2 diabetes (1,2). Obesity, dia-
betes, and insulin resistance are the main
risk factors for more advanced forms of
the disease; up to 70–80% of individuals
with NAFLD have insulin resistance or
metabolic syndrome (3). Currently, there
is no approved therapy, and identifying
an effective treatment remains a priority
area for research. In their last Medical Po-
sition Statement in 2002, the American
Gastroenterology Association and Ameri-
canAssociationfortheStudyofLiverDis-
eases stated that “Weight loss should be
considered in overweight patients with
NAFLD” (4). However, both organiza-
tions acknowledged that this recommen-
dation was based on clinical impressions
rather than on objective evidence.
Although a number of clinical studies
havebeenconductedsince1990toassess
theeffectoflifestylechangeand/orweight
loss on hepatic steatosis, these studies
have differed in treatment intensity and
have been limited by small study size,
short duration, and the presence of con-
founding by other factors related to
weight changes and NAFLD. In addition,
most studies have relied on nonspeciﬁc
(liver enzymes) or semiquantitative (ul-
trasound) outcomes to assess changes in
hepatic steatosis. Finally, large controlled
trials focused on patients with type 2 di-
abetes are lacking.
To ﬁll this gap, we conducted an an-
cillary study within the Look AHEAD
(ActionforHealthinDiabetes)trial,aNa-
tional Institutes of Health–funded, ran-
domized controlled trial investigating the
long-term health impact of an intensive
lifestyle intervention (ILI) in overweight
or obese adults with type 2 diabetes. We
hypothesized that the ILI would reduce
hepatic steatosis and incident NAFLD
compared with those of individuals in the
comparison group who received diabetes
support and education (DSE).
RESEARCH DESIGN AND
METHODS— This study was con-
ductedatoneofthe16LookAHEADclin-
ical sites (https://www.lookaheadtrial.
org/public/home.cfm). The design of the
Look AHEAD trial has been published
previously (5). In brief, participants were
eligible for the study if they were aged
between 45 and 76 years, had type 2 dia-
betes, had a BMI of at least 25 kg/m
2, and
were able to complete a maximal exercise
test. For the main Look AHEAD study,
participants were excluded if they had
known chronic liver disease, cirrhosis, or
inﬂammatory bowel disease requiring
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14 alcoholic drinks per week, had prior
bariatric surgery, were currently using
weight loss medications (e.g., sibutra-
mine, phentermine, and orlistat), or had
uncontrolled medical conditions (e.g.,
A1C 11% or blood pressure 160/100
mmHg), chronic use of systemic cortico-
steroids, or known conditions that would
limit their adherence to the study proto-
col (e.g., inability to engage in moderate
exercise) or their life span (e.g., cancer).
All participants were required to have a
regular source of medical care outside the
study.
After random assignment, all 318 par-
ticipants at The Johns Hopkins University
site were invited to participate in the Fatty
Liver Ancillary Study; 244 participants in
theILI(n124)andDSE(n120)groups
agreed. A representative sample of them
(n  185) also agreed to undergo proton
magneticresonancespectroscopy(
1HMRS)
and,ofthese,151hadsuccessful
1HMRSat
baseline. Of the 151 participants who com-
pleted a baseline
1H MRS, 102 successfully
underwent a 12-month
1H MRS and were
eligibleforthecurrentanalyses.Afterexclu-
sion for alcohol consumption (1 drink/
dayforwomenand2drinks/dayformen)
or other potential causes of liver disease
(see below) (total n  6), a total of 96
participants were included in the cur-
rent analyses (Fig. S1, available
in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc09-0856/DC1).
The study was reviewed and ap-
proved by local institutional review
board. All participants gave written in-
formed consent.
Measurements
As a part of both the parent Look AHEAD
trial and our ancillary study, participants
underwent extensive data collection at
baseline and 12 months after the inter-
vention. Age, sex, race/ethnicity, and
medication use were obtained by ques-
tionnaire. Lifetime alcohol use was esti-
mated using the Skinner Lifetime
DrinkingHistory(6).Weight,height,and
waist circumference were directly mea-
sured by trained data collectors using
standardized techniques. Blood samples
were obtained from all patients after an
overnight fast; analyses included serum
aminotransferases, A1C (NGSP-certiﬁed
autoanalyzer [G7 Tosoh] with interassay
coefﬁcients of variation [CVs]) of 0.9 and
0.6% for the low- and high-quality con-
trol samples, respectively), creatinine,
and lipid levels.
For those who completed the
1H
MRS, blood samples were also tested for
hepatitisBsurfaceantigen,hepatitisCan-
tibody, -1-antitrypsin phenotype, iron,
transferrin saturation, iron-binding ca-
pacity, antinuclear antibodies, antimito-
chondrial antibodies, and anti–smooth
muscle antibodies. After centrifugation,
serum for insulin, adipokines, cytokines,
and inﬂammatory markers were frozen at
70°F and subsequently hand trans-
ported on dry ice to the Core Laboratory
at The Johns Hopkins General Clinical
Research Center. After a single thaw, the
following assays were performed: inter-
leukin IL-8 (R&D Systems) (interassay
CV 10.32% and intra-assay CV 2.33%),
IL-10 (R&D Systems) (10.17% and
3.38%), tumor necrosis factor- (TNF-)
(R&D Systems) (8.79% and 7.0%), insu-
lin (Linco) (8.77% and 5.78%), ghrelin
(Linco) (5.72% and 5.17%), resistin
(ALPCO Diagnostics) (3.16% and
2.11%), and adiponectin (Linco) (3.5%
and 3.6%).
1H MRS was performed on a 1.5-T
whole-body scanner (Philips Gyroscan
ACS-NT; Philips Medical Systems, Best,
the Netherlands). Percent hepatic steato-
sis was calculated as fat/fat  water as
determined from proton magnetic reso-
nance spectra by integration of the
respective signals. In our center, the re-
producibility of steatosis measurement
by
1H MRS was excellent with intra- and
interrater intraclass correlation coefﬁ-
cients of 0.99.
Hepatic steatosis was deﬁned as
5.5% hepatic fat by
1H-MRS and
NAFLD as hepatic steatosis plus alcohol
consumption1drink/dayforwomenor
2 drinks/day for men and negative se-
rology for hepatitis B and hepatitis C.
To estimate intra-abdominal fat vol-
ume, eight axial magnetic resonance T1-
weighted spin echo images were also
acquiredatvertebralbodiesL2–L3duringa
single breath-hold and estimated using
“NIH Image” (http://rsb.info.nih.gov/nih-
image/Default.html). These measurements
were also highly reliable (intraclass correla-
tion coefﬁcients 0.96–0.99) (7).
Look AHEAD interventions
A description of the Look AHEAD inter-
vention has been published previously
(8). In brief, participants assigned to the
ILI were encouraged to lose at least 10%
of initial weight at 12 months through a
combination of moderate caloric restric-
tion (1,200–1,500 kcal/day for those in-
dividuals weighing 114 kg and 1,500–
1,800 kcal/day for those weighing 114
kg, with 30% calories from fat and
10% from saturated fat) and increased
physical activity with a goal of 175 min of
moderate intensity physical activity per
week. During the ﬁrst 6 months, partici-
pants attended weekly meetings, includ-
ing one individual and three group
sessions per month. During months
7–12, participants attended monthly in-
dividual session and the group sessions.
Participants assigned to the DSE
group attended three group sessions per
year,whichprovidedgeneralinformation
on nutrition, physical activity, and social
support. DSE participants were given no
individual goals, were not weighed dur-
ingthesessions,andreceivednocounsel-
ing in behavioral strategies for changing
diet and physical activity.
Statistical analysis
Twelve-month changes in measures of
adiposity, biochemical and metabolic pa-
rameters, adipokines and cytokines, and
medication use by group were assessed
using ANCOVA. Despite the randomized
design of the parent study, our study
groups were not comparable in all re-
spects. To address these imbalances, we
adjusted all of our analyses by differences
in sex, baseline weight, and baseline he-
patic steatosis.
We analyzed changes in steatosis us-
ing two approaches: ﬁrst as the absolute
difference between 12 months and base-
line (change steatosis  steatosis [per-
cent]) at 12 months minus steatosis
[percent] at baseline) and then as relative
difference (percent change steatosis 
[(steatosis [percent] at 12 months minus
steatosis [percent] at baseline)/steatosis
[percent]atbaseline]100).Becausethe
distributionofpercentchangeinsteatosis
was skewed, we used quintile regression
methods to model the median percent
change steatosis from baseline to 12
months in hepatic steatosis in the ILI
compared with the DSE group, adjusting
for other covariates.
We used multivariate regression analy-
ses to assess the inﬂuence of potential me-
diators of the intervention including
changes in weight and other measures of
adiposity, metabolic parameters, and adi-
pokines and cytokines. First, we assessed
theroleofchangesinotheradipositydepos-
its. Second, we evaluated changes in meta-
bolic parameters and, third, we determined
changes in adipokines and cytokines. All
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weight, and baseline steatosis.
To assess the correlations between
hepatic steatosis and other parameters we
usedpartialSpearmanrankcoefﬁcientsto
accountforthenonnormaldistributionof
liver fat while adjusting for treatment
group and sex. The odds of incident
NAFLDwasassessedusinglogisticregres-
sion and included only individuals with
baseline steatosis 5.5%.
RESULTS
Baseline characteristics
We included 96 participants randomly as-
signed to ILI (n  46) and DSE (n  50).
ThesamplehadameanSDageof61.6
6.7 years and BMI of 34.9  5.0 kg/m
2;
60% were white, 32% were African Ameri-
can,5%wereother,and2%wereHispanic.
Overall 49% were women, with slightly
more women in the ILI group than in the
DSEgroup(59vs.40%P0.06).A1Cwas
7.2  1.0%, and 87% of participants were
using any diabetes medication, including
12% taking insulin and 50% taking met-
Table 1—Baseline and 1-year characteristics of Look AHEAD participants
Variable
ILI (intervention)
Baseline 1 year Absolute change Relative change
n 46
Measures of adiposity
Hepatic fat 4.2 (2.37.2)* 2.9 (1.33.9) 2.3 (4.3 to 0.4) 50.8 (66.9 to 27.8)
01 (%) 7 (15.2) 8 (17.4)
1.15.49 (%) 24 (52.2) 29 (63.0)
5.510 (%) 5 (10.9) 5 (10.9)
10.120 (%) 8 (17.4) 3 (6.5)
20 (%) 2 (4.4) 1 (2.2)
BMI 34.7  5.4 32.1  5.2 2.6  2.6 7.3  6.8
2529.9 kg/m
2 8 (17.4) 15 (68.2)
3034.9 kg/m
2 21 (44.7) 20 (43.5)
3539.9 kg/m
2 12 (26.1) 9 (19.6)
40 kg/m
2 5 (10.9) 2 (4.4)
Weight (kg) 98.1  16.6* 90.6  14.9 8.5  8.3 8.3  6.9
Waist circumference (cm) 112.0  11.7* 102.4  11.7 9.9  11.1 8.4  8.9
Total fat (per 10 cm
2) 51.3  15.4 46.4  14.8 5.3  11.0 8.8  17.2
Subcutaneous (per 10 cm
2) 28.8  13.2 26.6  11.8 2.9  7.2 6.7  19.2
Intraperitoneal (per 10 cm
2) 15.5  6.6 13.0  5.5 2.5  4.4 12.7  28.5
Retroperitoneal (per 10 cm
2) 5.8  2.7 5.9  3.1 0.2  1.6 5.3  27.4
Biochemical and metabolic parameters
ALT (units/l) 17.5 (1428) 20 (1627) 1 (3t o7 )
AST (units/l) 18 (1524) 21 (1825) 3 (2t o5 )
ALTtoAST ratio 1 (0.81.1) 1 (0.81.2) 0.1 (0.2 to 0.2)
GGT (units/l) 24 (1836) 22 (17.532.0) 3( 6t o1 )
A1C (%) 7.1  1.0 6.5  0.9 0.7  1.1
HDL cholesterol (mg/dl) 47.9  11.7 52.7  12.0 4.1  7.0
Triglycerides (mg/dl) 111.5 (88169) 107 (66139) 5( 46 to 18)
LDL cholesterol (mg/dl) 118.0  34.5 107.3  30.7 9.3  23.3
HDLtotriglyceride ratio 2.3 (1.63.9) 2.1 (1.313.1) 0.2 (1.1 to 0.3)
Adipokines and cytokines
IL8 (pg/ml) 31.7 (24.338.2) 23.0 (17.029.6) 9.3 (17.3 to 5.9)
IL10 (pg/ml) 5.5 (4.85.9) 6.8 (5.57.8) 0.9 (0.2 to 3.0)
TNF (pg/ml) 1.7 (1.22.6) 1.7 (1.42.2) 0.2 (0.7 to 0.6)
Adiponectin (	g/ml) 5.9 (4.57.2) 11.5 (7.6721.21) 6.7 (2.4 to 10.8)
Ghrelin (ng/ml) 1.2 (0.92.0) 1.4 (0.91.8) 0.03 (0.9 to 0.7)
Resistin (ng/ml) 4.1 (2.96.6) 6.8 (4.78.8) 1.9 (0.5 to 2.6)
Medications
No. of diabetes medications 1.3  0.8 1.2  0.9 0.1  0.5
01 29 (63.0) 30 (65.2)
2 12 (26.1) 11 (23.9)
3 5 (10.9) 5 (10.9)
Use of insulin (%) 13 11 2
Use of metformin (%) 52.20 45.70 6.5
Use of thiazolidinedione (%) 28.30 23.90 4.4
Use of lipid-lowering drug (%) 41.3* 45.70 4.4
Data are means  SEM, median (interquartile range), or frequency (%). *ILI vs. DSE baseline difference P  0.05, adjusted for sex and baseline weight.
Lifestyle intervention and hepatic steatosis
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the main Look AHEAD trial, the ﬁnal sam-
ple included a subset of the randomly as-
signed participants, and there were
signiﬁcant differences in baseline weight,
steatosis, waist circumference, and use of
lipid-lowering medications between the
groups (Table 1). Hepatic steatosis
(5.5%) was present in 44% including 15
(36%) in the ILI group and 27 (64%) in the
DSE group (P  0.04). All analyses were
adjusted for these baseline differences.
Baseline levels of alanine aminotrans-
ferase (ALT), aspartate aminotransferase
(AST), and 
-glutamyl transferase (GGT)
were 23.9, 20.4, and 45.1 units/l, respec-
tively,anddidnotdifferbygroup(allP
0.05). Overall, 6 participants (6%) had
elevated ALT levels (40 units/l) and 43
(45%) had an AST-to-ALT ratio 1.
12-Month changes in steatosis,
adiposity, and other metabolic
parameters
As shown in Table 1, the ILI was effective
and resulted in signiﬁcant decreases in
BMI (2.6 vs. 0.03 kg/m
2; P  0.001),
weight (8.5 vs. 0.05 kg; P  0.001),
percent weight (8.3 vs. 0.03%; P 
0.001), waist circumference (9.5 vs.
1.8 cm; P  0.001), percent total fat
Table 1—Continued
DSE (control) P value deltas
(ILI vs. DSE) 1 year Baseline 1 year Absolute change Relative change
50
6.3 (2.712.7) 4.9 (1.98.6) 1.1 (3.1 to 1.2) 22.8 (51.2 to 32.2) 0.04
5 (10.0) 6 (12.2)
18 (36.0) 20 (40.8)
9 (18.0) 13 (26.5)
14 (28.0) 6 (12.2)
4 (8.0) 4 (8.2)
35.3  4.7 35.3  4.8 0.02  2.0 0.03  5.7 0.001
3 (6.0) 7 (14.0)
26 (52.0) 19 (38.0)
14 (28.0) 15 (30.0)
7 (14.0) 9 (18.0)
104.8  16.7 104.7  16.9 0.05  5.7 0.02  5.2 0.001
115.0  11.8 113.5  12.4 1.8  6.5 1.4  5.5 0.001
56.0  14.5 56.0  15.6 0.03  7.8 0.5  14.1 0.002
29.1  10.3 28.4  10.7 0.8  4.16 1.9  16.8 0.02
18.7  7.7 18.2  7.3 0.4  4.4 1.8  24.4 0.02
7.1  3.2 8.2  4.1 1.1  2.0 15.4  26.6 0.05
20 (1726) 19 (1424) 2( 6 to 1) 0.31
19 (1524) 17 (1522) 0 (3 to 2) 0.45
0.8 (0.71) 0.9 (0.81.1) 0.1 (0.04 to 0.2) 0.19
25 (2245) 23 (1835) 4( 11 to 2) 0.27
7.3  1.0 7.1  1.0 0.2  0.8 0.04
42.9  12.0 44.2  11.4 2  6.5 0.11
122.5 (91194) 121 (87190) 5( 31 to 20) 0.23
109.8  29.9 98.1  27.7 12.3  25.0 0.53
3.2 (2.15.4) 2.6 (1.94.7) 0.2 (0.9 to 0.4) 0.4
31.9 (21.141.7) 21.0 (15.926.3) 9.3 (21.1 to 0.1) 0.65
5.3 (4.86.4) 7.1 (5.98.7) 1.4 (0.043.4) 0.08
1.8 (1.42.8) 1.9 (1.62.5) 0.03 (0.7 to 0.7) 0.82
5.4 (4.36.3) 9.3 (6.815.2) 3.8 (1.7 to 8.9) 0.1
1.2 (0.92.1) 0.9 (0.81.2) 0.3 (1.1 to 0.2) 0.35
4.5 (3.55.9) 6.2 (4.88.2) 1.5 (0.1 to 3.0) 0.84
1.4  0.8 1.5  0.8 0.1  0.6 0.06
27 (44.0) 22 (44.0)
19 (38.0) 23 (46.0)
4 (8.0) 5 (10.0)
10 8 2 0.94
48 54.20 6.2 0.38
34 30.00 4 0.95
70 70.80 0.8 0.82
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subcutaneous fat (6.7 vs. 1.9%; P 
0.02), and percent intraperitoneal fat
(12.7 vs. 1.8%; P  0.02) compared
with the DSE. These ﬁndings are similar
to the 1-year results of the main Look
AHEAD trial (9).
After adjustment for sex, baseline
weight, and baseline steatosis, the 12-
month median absolute change in steato-
sis in the ILI group was more than double
that in theDSEgroup (2.3 vs. 1.1; P
0.04). The median percent decrease in ste-
atosis was 50.8% in the ILI group and
22.8% in the DSE group (P  0.04).
Participants in the ILI group also had
signiﬁcant decreases in A1C (0.7 vs.
0.2%;P0.04).Thisdifferenceinglu-
cosecontroloccurreddespitethefactthat
the proportion of individuals using any
diabetes medicine decreased from base-
line in the ILI group compared with that
in the DSE group. No statistically signiﬁ-
cantdifferenceswereobservedinliveren-
zymes or lipids at 12 months.
Variables associated with changes in
hepatic steatosis
As shown in Table 2, after adjustment for
intervention group and sex, absolute
changes in steatosis were signiﬁcantly
correlated with changes in weight (r 
0.231, P  0.03), A1C (r  0.311, P 
0.004), glucose (r  0.291, P  0.007),
and ALT, AST, and GGT (r  0.294, r 
0.348 and r  0.277, all P  0.001). No
signiﬁcant correlations were found be-
tween absolute changes in steatosis and
changes in any measured cytokine or adi-
pokine. On a relative scale, the percent
change in liver fat showed signiﬁcant and
strong correlation coefﬁcients with
changes in all of the above parameters. In
addition, percent change in steatosis was
signiﬁcantly correlated with changes in
BMI (r  0.259, P  0.02), insulin levels
(r  0.302, P  0.02), triglycerides
(r  0.336, P  0.002), and the HDL-to-
triglyceride ratio (r  0.276, P  0.011).
Greater weight loss was associated
with the largest decreases in steatosis.
Compared with those with little weight
change (1%), those with the largest
weight loss (10%) had a signiﬁcantly
highermedianpercentreductioninsteato
sis of 79.5 vs. 13.7% (Fig. 1). We
used multivariate models to assess
whether these correlations were indepen-
dently associated with changes in steato-
sis. After adjustment for any of the
following: changes in weight, changes in
BMI, changes in retroperitoneal fat,
changes in A1C, changes in triglycerides,
and changes in the HDL-to-triglyceride
ratio as well as sex, treatment group, and
baseline weight and hepatic fat, the effect
of the intervention was no longer signiﬁ-
cant. Changes in adipokines or cytokines
did not attenuate the effect of the
intervention.
NAFLD incidence
Finally, during the 12-months of follow-
up, 6 of 23 (26%) DSE participants and 1
of 31 (3%) ILI participants without
NAFLD at baseline developed NAFLD at
12 months (odds ratio 0.07 [95% CI
0.007–0.71]).
CONCLUSIONS— Among adults
with type 2 diabetes, 12 months of an in-
tensive lifestyle intervention leading to
8% loss of body weight was successful in
both reducing hepatic steatosis and de-
creasing the risk of incident NAFLD,
compared with those in a control group
Furthermore, a dose-response relation-
ship was observed with weight loss, with
the greatest reduction observed in those
with the greatest weight loss (10%).
Our ﬁndings therefore support the cur-
rent recommendation for weight loss us-
ing lifestyle modiﬁcation as the ﬁrst step
in the management of patients with
NAFLD, including patients with type 2
diabetes and for those at risk for NAFLD.
We found that the decrease in steato-
sis was nearly double in the ILI group
compared with that in the DSE group. In
addition, as in the main Look AHEAD
1-year results (9), the use of overall and
speciﬁc medications such as thiazo-
lidinedione and metformin tended to de-
crease more among the intervention arm.
We would anticipate that these differ-
ences would then favor the control arm,
leading to a more conservative estimate.
These ﬁndings are important because
NAFLD not only disproportionately af-
fects individuals with type 2 diabetes but
also because once NAFLD is present, the
risk of developing more advanced forms
Table2—Correlationofchangesinliverfatwithchangesinotherparameters,adjustedforsex
and intervention group
Absolute  liver fat P value Percent  liver fat P value
Measures of adiposity
 weight 0.231 0.030 0.349 0.001
 waist 0.022 0.835 0.116 0.281
 BMI 0.194 0.070 0.259 0.015
 total fat 0.095 0.378 0.097 0.367
 subcutaneous fat 0.135 0.209 0.111 0.304
 intraperitoneal fat 0.056 0.604 0.045 0.676
 retroperitoneal fat 0.080 0.456 0.145 0.179
Metabolic parameters
 A1C 0.311 0.004 0.419 0.0001
 glucose 0.291 0.007 0.373 0.001
 insulin* 0.186 0.137 0.302 0.015
 total cholesterol 0.050 0.654 0.042 0.701
 HDL 0.072 0.517 0.005 0.964
 triglycerides 0.187 0.089 0.336 0.002
 LDL 0.084 0.447 0.105 0.342
 HDL-to-triglyceride ratio 0.128 0.246 0.276 0.011
Liver tests
 ALT 0.294 0.005 0.211 0.047
 AST 0.348 0.001 0.280 0.008
 GGT 0.277 0.009 0.287 0.006
 AST-to-ALT ratio 0.030 0.781 0.033 0.762
Inﬂammatory markers
 IL-8 0.014 0.904 0.085 0.466
 IL-10 0.136 0.245 0.010 0.934
 TNF- 0.024 0.840 0.002 0.986
 adiponectin 0.062 0.600 0.124 0.290
 ghrelin 0.195 0.094 0.214 0.065
 resistin 0.122 0.297 0.079 0.498
*Among non–insulin users.
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hepatitis and hepatocellular carcinoma is
higher in this group than in the general
population (3,10–13).
Our results are consistent and extend
previous trials of weight loss for patients
with NAFLD, suggesting improvement in
hepatic steatosis. To our knowledge there
havebeenatotalofnineclinicalstudiesof
lifestyle intervention on hepatic steatosis
measured by
1H MRS (14–22), and, of
these, only two have been conducted
among individuals with type 2 diabetes
(17,18). Petersen et al. (17) treated eight
individuals with obesity and diabetes
with a 1,200-calorie liquid diet for 3–12
weekstoachieve8%weightloss.Steatosis
decreased on average 81% (from 12 to
2.2%). Tamura et al. (17) randomly as-
signed 14 subjects to a controlled diet
only(25–30kcal/kgidealbodyweight)or
exercise and diet (same diet plus two or
three 30-min sessions of walking 5–6
days/week) for 2 weeks. In this inpatient
study, the mean decreases in hepatic ste-
atosis were 25 and 28% for the diet only
and diet plus exercise group, respectively
(18). Our study extends these ﬁndings in
patientswithtype2diabetesbyincluding
a larger and diverse sample and a longer
intervention.
Because most participants had nor-
mal liver enzymes at baseline, it is under-
standable that there was no signiﬁcant
change with weight loss and decrease in
steatosis. However, consistent with other
studies, our data show that normal liver
test results are not good indicators of the
presence or absence of hepatic steatosis.
Cytokines and adipokines have been
posited to play an important role as me-
diators of improved hepatic insulin sensi-
tivity with weight loss. In our study,
changes in steatosis and adiposity were
not associated with changes in IL-8, IL-
10, TNF-, adiponectin, ghrelin, or resis-
tin. These results are consistent with two
other previous studies (16,17) and sug-
gest that among individuals with type 2
diabetes these may not play a major role
inchanginginsulinsensitivityintheliver.
Although a clinically meaningful
change in steatosis remains to be deﬁned,
our results suggest that among patients
with type 2 diabetes, reduction in hepatic
steatosis is signiﬁcantly associated with
levels of A1C and triglycerides, both of
which are important markers of disease
risk and control (23). Longer studies are
needed to identify meaningful changes in
liver fat, with respect to liver outcomes.
Ourstudyhassomelimitations.First,
wehadnohistopathologicaldatatoassess
theeffectoftheintervention.Although
1H
MRS is an excellent method to quantify
changes in steatosis because it is noninva-
sive and reliable, it cannot assess inﬂam-
mationorﬁbrosis.Recently,Promratetal.
(24)reportedtheresultsofansmallertrial
of lifestyle intervention for 31 overweight
patientswithbiopsy-provennonalcoholic
steatohepatitis, and their results are in
agreement with our ﬁndings. In addition,
ourstudyincludedolderindividualswith
type 2 diabetes and mostly with normal
liver enzyme levels, probably reﬂecting a
different spectrumof the disease. Second,
eventhoughthistrialisbyfaristhelargest
ofitskind,thestudysamplewasnotlarge
enough to study participant subgroups
(i.e., sex and race or to assess sex-
treatment or race-treatment interactions).
Third, we studied participants in a large
randomized clinical trial who are likely to
Figure 1—Median percent change in hepatic steatosis by percent weight change.
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ever, although limiting generalizability,
this setting is ideal to assess the efﬁcacy of
this intervention. Future studies will be
needed to assess the effectiveness of this
approach.Fourth,eventhoughtheparent
studyhadarandomizeddesign,ourstudy
groups were not comparable in all re-
spects, probably because enrollment into
this ancillary study occurred after ran-
domization and by random chance. To
address these imbalances we adjusted all
ouranalysesbythesebaselinedifferences.
Finally, because obesity hinders the suc-
cessful acquisition of
1H MRS, the results
may be conservative.
In summary, in patients with type 2
diabetes, an intensive lifestyle interven-
tion that produced 8% weight loss re-
sulted in a signiﬁcant, 25% greater
reduction in hepatic steatosis and a sub-
stantiallylowerincidenceofNAFLDcom-
pared with that of a comparison group
after 12 months of the intervention. The
long-term efﬁcacy as well as the effective-
ness of an intensive lifestyle intervention
needs to be further established.
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